Hereditary Paraganglioma is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Hereditary paraganglioma syndromes are autosomal dominant disorders characterized by the development of tumors in the paraganglia, which are collections of neuroendocrine cells distributed throughout the head, neck, thorax, and abdomen. These tumors arise from the sympathetic and parasympathetic nervous systems and can produce catecholamines. The hereditary forms account for approximately 40% of all paragangliomas and are associated with germline mutations in genes encoding mitochondrial succinate dehydrogenase (SDH) complex subunits, highlighting the fundamental role of mitochondrial dysfunction in tumor pathogenesis.
Hereditary paraganglioma syndrome (HPS) represents a paradigm of mitochondrial tumor predisposition, where germline mutations in oxidative phosphorylation genes lead to tumor development through pseudohypoxic drive and dysregulated cellular metabolism. The syndrome demonstrates remarkable genotype-phenotype correlations, with specific gene mutations determining tumor location, catecholamine secretion patterns, and malignant potential.
The condition follows an autosomal dominant inheritance pattern with maternal imprinting for SDHD, meaning that disease expression typically requires paternal transmission of the mutant allele. This unique inheritance pattern results in affected individuals often having an affected father, while the mother may carry the mutation without developing tumors.
The SDHx genes encode subunits of succinate dehydrogenase (SDH), also known as mitochondrial Complex II, which plays a critical role in both the electron transport chain and the Krebs cycle:
| Gene | Protein | Chromosome | Tumor Risk | Malignancy Rate |
|---|---|---|---|---|
| SDHD | Subunit D | 11q23 | High | 5-10% |
| SDHB | Subunit B | 1p36 | Very high | 30-50% |
| SDHC | Subunit C | 1q23 | Moderate | <5% |
| SDHAF2 | Assembly factor | 11q13 | High | <5% |
Beyond the core SDHx subunits, mutations in SDHAF2 (also called SDH5) impair SDH assembly and function. Additional susceptibility genes include:
The loss of functional SDH leads to several interconnected pathogenic mechanisms:
Hereditary paragangliomas develop in characteristic locations depending on the underlying genetic mutation:
Head and Neck (Parasympathetic)
Thorax (Sympathetic)
Abdomen (Sympathetic)
Clinical manifestations depend on tumor location and catecholamine secretion:
Initial evaluation includes biochemical assessment of catecholamine metabolism:
Localize tumors and assess for metastatic disease:
Given the high hereditary rate, genetic counseling and testing are essential:
Surgery remains the primary treatment modality:
For unresectable or residual disease:
For malignant or metastatic disease:
Long-term monitoring is critical:
The mitochondrial dysfunction in hereditary paraganglioma shares mechanisms with neurodegenerative diseases:
Epidemiological studies suggest potential links between SDHx variants and Parkinson's disease risk:
Understanding these connections suggests potential therapeutic strategies:
The study of Hereditary Paraganglioma has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Neumann HP, Young WF Jr, Eng C. Pheochromocytoma and Paraganglioma. N Engl J Med. 2019;381(6):552-565. PMID:31390500.
Bayley JP, van Minderhout I, Hogendoorn PC, et al. SDHA and SDHB mutation spectrum: a Dutch cohort. J Med Genet. 2010;47(10):687-692. PMID:20921025.
Jeschke J, Ziegler L, Keitz S, et al. Mitochondrial contributions to tumor pathogenesis and therapeutic targeting. Nat Rev Cancer. 2023;23(5):351-367. PMID:37012452.
Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366(9486):665-675. PMID:16109904.
Fishbein L, Merrill S, Fraker DL, Cohen DL, Nathanson KL. Inherited mutations in pheochromocytoma and paraganglioma: importance of sequential biochemical and genetic testing. J Clin Endocrinol Metab. 2013;98(3):E587-E599. PMID:23471971.
Favier J, Briere JJ, Burnichon N, et al. The warburg effect is genetically determined in inherited pheochromocytomas. PLoS One. 2009;4(7):e6294. PMID:19609446.
Ray K. Parkinson's disease: shared mechanisms between pheochromocytoma and neurodegeneration. Nat Rev Neurol. 2018;14(8):453-454.
Taïeb D, Kalisvaart M, Brogdon S, et al. Comparison of 68Ga-DOTATATE and 123I-MIBG imaging for pheochromocytoma. J Clin Endocrinol Metab. 2022;107(7):e2917-e2928. PMID:35460283.
Gimenez-Roqueplo AP, Favier J, Rustin P, et al. Mutations in the SDH subunit genes increase ROS and predispose to cancer. Cancer Res. 2003;63(10):2585-2590. PMID:12750283.
Timmers HJ, Pacak K, de Krijger RR. Biochemical and genetic diagnosis of pheochromocytoma. Nat Rev Endocrinol. 2024;20(10):607-619. PMID:38965321.